Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 11: Raleigh bar permanently closed after more than 20 years of service. The investigation that prompted the owner to shut down
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
203.30
-1.56 (-0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
39
40
Next >
Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff
July 25, 2023
Biogen Inc (NASDAQ: BIIB) posted Q2 FY23 sales of $2.46 billion, beating the con
Via
Benzinga
Biogen Inc. Tops Q2 Earnings And Revenue Estimates
July 25, 2023
Biogen Inc. came out with quarterly earnings of $4.02 per share.
Via
Talk Markets
Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting'
July 25, 2023
Via
Benzinga
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
July 24, 2023
Analysts expect Biogen to report a a decline in both profits and sales in Q2.
Via
Investor's Business Daily
Better Big Biotech Buy: Vertex vs. Biogen
July 24, 2023
These companies have a track record of billion-dollar earnings.
Via
The Motley Fool
Biogen Earnings Preview
July 24, 2023
Via
Benzinga
Biogen Unusual Options Activity
July 21, 2023
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
July 20, 2023
Via
Benzinga
Is Biogen Stock a Buy Now?
July 19, 2023
The biotech hasn't been the best investment recently.
Via
The Motley Fool
Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades'
July 21, 2023
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc.
Via
Benzinga
Should You Buy the Dip With Biogen Stock Right Now?
July 17, 2023
It's expected to grow, but things might not work out precisely as planned.
Via
The Motley Fool
These 2 Numbers Should Scare Every Biogen Shareholder
July 16, 2023
There are a couple of pieces of evidence that Biogen's long-term strategy isn't working.
Via
The Motley Fool
7 Stocks That AI Says Will Make You a Millionaire by 2025
July 13, 2023
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio.
Via
InvestorPlace
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
July 13, 2023
Is the stock a good contrarian buy?
Via
The Motley Fool
P/E Ratio Insights for Biogen
July 12, 2023
Via
Benzinga
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?
July 09, 2023
Biogen shares are little changed year to date.
Via
The Motley Fool
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today
July 07, 2023
Via
Benzinga
What 29 Analyst Ratings Have To Say About Biogen
July 07, 2023
Via
Benzinga
Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets
July 07, 2023
Via
Benzinga
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and...
Via
Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
July 07, 2023
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Via
Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
July 07, 2023
Automakers rallied on sales while Meta's Threads had a big launch.
Via
Investor's Business Daily
What's Going On With Biogen Stock Thursday
July 06, 2023
Biogen Inc (NASDAQ: BIIB) shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during
Via
Benzinga
FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today
July 07, 2023
First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility.
Via
InvestorPlace
Why Is Alibaba (BABA) Stock Up Today?
July 07, 2023
Alibaba (BABA) stock is on the rise Friday as investors react to a few pieces of news considering the Chinese e-commerce giant.
Via
InvestorPlace
BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug
July 07, 2023
Biogen (BIIB) stock is in the news Friday after the pharmaceutical company got approval from the FDA for its Alzheimer's drug.
Via
InvestorPlace
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
July 07, 2023
Via
Benzinga
Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval
July 06, 2023
Via
Benzinga
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
July 06, 2023
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers
Via
InvestorPlace
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
July 06, 2023
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug.
Via
Investor's Business Daily
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.